Centessa Pharmaceuticals Aktie

19,50 EUR -0,70 EUR -3,47 %

07:36:51

STU

22,74 USD -0,26 USD -1,13 %

19:21:54

BTT

Centessa Pharmaceuticals jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 11/2024)

Jetzt loslegen

Direkt handeln

Bei einem anderen Broker handeln

Div. Rendite0,00%

WKNA3CQ72

ISINUS1523091007

SymbolCNTA

Centessa Pharmaceuticals Aktien News

Sortieren:Datum Meistgelesen

14.05.25GlobeNewswireCentessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2025

24.03.25GlobeNewswireCentessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024

12.11.24GlobeNewswireCentessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update

WerbungCentessa Pharmaceuticals-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

13.09.24GlobeNewswireCentessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares

11.09.24GlobeNewswireCentessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares

10.09.24GlobeNewswireCentessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers

27.08.24GlobeNewswireCentessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research

13.08.24GlobeNewswireCentessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024

13.05.24GlobeNewswireCentessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024

24.04.24GlobeNewswireCentessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares

23.04.24GlobeNewswireCentessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares

22.04.24GlobeNewswireCentessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024

28.03.24GlobeNewswireCentessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023

10.12.23GlobeNewswireCentessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia

13.11.23GlobeNewswireCentessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023

25.10.23GlobeNewswireCentessa Pharmaceuticals Announces Preclinical Data Supporting ORX750’s Potential as a Best-in-Class Oral OX2R Agonist for the Treatment of Narcolepsy and Other Sleep-Wake Disorders

14.08.23GlobeNewswireCentessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2023

10.07.23GlobeNewswireCentessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-2 Study Evaluating SerpinPC for the Treatment of Hemophilia B without Inhibitors

24.05.23GlobeNewswireCentessa Pharmaceuticals to Participate in Upcoming Investor Conferences

22.05.23GlobeNewswireCentessa Pharmaceuticals Receives Fast Track Designation from the U.S. FDA for SerpinPC for Hemophilia B

12.05.23GlobeNewswireCentessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2023

30.03.23GlobeNewswireCentessa Pharmaceuticals Reports Recent Business Progress and Financial Results for the Fourth Quarter and Full-Year 2022

27.03.23GlobeNewswireCentessa Pharmaceuticals to Participate in Upcoming Investor Conferences

23.03.23PR NewswireClarivate Announces Gordon Samson as President, Intellectual Property and Nominates Dr. Saurabh Saha as New Independent Director

01.03.23GlobeNewswireCentessa Pharmaceuticals Announces Addition of Patrick Yue, MD, as Senior Vice President of Clinical Development, Innovative Medicines

28.11.22PR NewswireDEADLINE TODAY: The Schall Law Firm Encourages Investors in Centessa Pharmaceuticals plc with Losses of $100,000 to Contact the Firm

22.11.22PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Centessa Pharmaceuticals plc of Class Action Lawsuit and Upcoming Deadline - CNTA

14.11.22PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Centessa Pharmaceuticals plc of Class Action Lawsuit and Upcoming Deadline - CNTA

10.11.22GlobeNewswireCentessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2022

03.11.22GlobeNewswireCentessa Pharmaceuticals to Present Additional 18-Months of Continued Treatment Data with SerpinPC from Open-Label Extension of Phase 2a Study at 64th ASH Annual Meeting

03.11.22PR NewswireCNTA LAWSUIT ALERT: Levi & Korsinsky Notifies Centessa Pharmaceuticals plc Investors of a Class Action Lawsuit and Upcoming Deadline

31.10.22GlobeNewswireCentessa Pharmaceuticals to Participate in Upcoming Investor Conferences

31.10.22PR NewswireCLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Centessa Investors of a Lead Plaintiff Deadline of November 28, 2022

29.10.22PR NewswireCENTESSA PHARMACEUTICALS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Acti...

21.10.22PR NewswireCNTA SHAREHOLDER ALERT: Jakubowitz Law Reminds Centessa Shareholders of a Lead Plaintiff Deadline of November 28, 2022

19.10.22PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Centessa Pharmaceuticals plc of Class Action Lawsuit and Upcoming Deadline - CNTA

11.10.22PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Centessa Pharmaceuticals plc of Class Action Lawsuit and Upcoming Deadline - CNTA

Centessa Pharmaceuticals News

Centessa Pharmaceuticals News: auf dieser Seite finden Sie alle Centessa Pharmaceuticals News und Nachrichten zur Centessa Pharmaceuticals Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Centessa Pharmaceuticals News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Centessa Pharmaceuticals News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.